Published in BMJ Case Rep on January 30, 2014
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol (2015) 0.79
Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Intern Med (2016) 0.75
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2013) 2.80
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist (2011) 1.03
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol (2012) 0.99
Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med (2012) 0.90
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol (2009) 0.81
Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature. Clin Genitourin Cancer (2013) 0.81
Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. Eur Urol (2011) 1.39
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer. Adv Ther (2013) 0.80
A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy. Med Phys (2011) 0.78
Some forms of knowledge are more equal than others. BMJ (2012) 0.78
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol (2012) 0.77
Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clin Genitourin Cancer (2012) 0.76
Patients with cancer say yes to palliative chemotherapy. BMJ (2013) 0.75
The return of the snake oil salesmen: the sequel. Int J Radiat Oncol Biol Phys (2012) 0.75
Salvage radiotherapy after high intensity focused ultrasound for prostate cancer. BMJ Case Rep (2012) 0.75
International register of trial acronyms. Lancet (2004) 0.75
Cancer patients' anxiety. Lancet (2003) 0.75
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report. Clin Genitourin Cancer (2012) 0.75
Degree of Rectal Distension Seen on Prostate Radiotherapy Planning CT Scan Is Not a Negative Prognostic Factor in the Modern Era of Image-Guided Radiotherapy. Oncology (2015) 0.75